Drug intelligence / Profile preview

XSTEM-VLU

Development stage: Phase 2
Lead developer: Xintela
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intralesional

Overview

XSTEM-VLU is an investigational cell therapy product designed for the treatment of chronic wounds, specifically venous leg ulcers. It is based on allogeneic mesenchymal stem cells (MSCs) derived from healthy donors. The therapy aims to promote wound healing by leveraging the regenerative and immunomodulatory properties of MSCs, which can enhance tissue repair and modulate inflammation in chronic wounds. The product is being developed for use in patients with hard-to-heal venous leg ulcers. The developer and manufacturer is Xintela.

Brand names: XSTEM-VLU

Beyond the preview

Go deeper on XSTEM-VLU.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XSTEM-VLU.

Explore the full profile